Expression of the TNF and the necessity of TNF receptors in bleomycin- induced lung injury in mice

Experimental Lung Research

Volumn 24, Issue 6, 1998, Pages 721-743

  Ortiz, Luis A ^a   Lasky, Joseph ^a   Hamilton Jr , Raymond F ^b   Holian, Andrij ^b   Hoyle, Gary W ^a   Banks, William ^a   Peschon, Jacques J ^c   Brody, Arnold R ^a   Lungarella, Giuseppe ^d   Friedman, Mitchell ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c AMGEN INC   (United States)

^d UNIVERSITY OF SIENA   (Italy)

Author keywords

Cytokines; Fibrosis; In situ hybridization; Macrophages; Strain susceptibility

Indexed keywords

TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEMALE; LUNG FIBROSIS; LUNG INJURY; MACROPHAGE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PNEUMONIA; PRIORITY JOURNAL;

EID: 7844226301     PISSN: 01902148     EISSN: None     Source Type: Journal    
DOI: 10.3109/01902149809099592     Document Type: Article

References (45)

1. Jules-Elyse K, White DA. Bleomycin-induced pulmonary toxicity. Clin Chest Med. 1990:11:1-20.
2. Chandler DB. Possible mechanisms of bleomycin-induced fibrosis. Clin Chest Med. 1990;11:21-30.
3. Bowden DH. Unraveling pulmonary fibrosis: the bleomycin model. Lab Invest. 1984;50:487-188.
4. Adamson IY, Bowden DH. The pathogenesis of bleomycin-induced pulmonary fibrosis in mice. Am J Pathol. 1974;77:185-197.
5. Lindenschmidt RC, Tryka AF, Godfrey GA, Frome EL, Witschi H. Intratracheal versus intravenous administration of bleomycin in mice: acute effects. Toxicol Appl. Pharmacol. 1986;85:69-77.
6. Harrison JH, Lazo JS. High dose continuous infusion of bleomycin in mice: a new model for drug-induced pulmonary fibrosis. J Pharmacol Exp Ther. 1987;243:1185-1194.
7. Schrier DJ, Kunkel RG, Phan SH. The role of strain variation in murine bleomycin-induced pulmonary fibrosis. Am Rev Resp Dis. 1983;127:63-66.
8. Rossi GA, Szapiel S, Ferrans VJ, Crystal RG. Susceptibility to experimental interstitial lung disease is modified by immune-and non-immune-related genes. Am Rev Respir Dis. 1987;135:448-455.
9. Harrison JH, Hoyt DG, Lazo JS. Acute pulmonary toxicity in bleomycin: DNA scission and matrix protein mRNA levels in bleomycin-sensitive and -resistant strains of mice. Molec Pharmacol. 1989;36:231-238.
10. Hoyt DG, Lazo JS. Murine strain differences in acute lung injury and activation of poly (ADP-ribose) polymerase by in vitro exposure of lung slices to bleomycin. Am J Respir Cell Mol Biol. 1992;7:645-651.
11. Baecher-Allan CM, Barth RK. PCR analysis of cytokine induction profiles associated with mouse strain variation in susceptibility to pulmonary fibrosis. Reg Immuno. 1993;5:207-217.
12. Piguet PF, Collart MA, Grau GE, Kapanci Y, Vassalli P. Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med. 1989;170:655-663.
13. Phan SH, Kunkel SL. Lung cytokine production in bleomycin-induced pulmonary fibrosis. Exp Lung Res. 1992;18:29-43.
14. Miyazaki Y, Tashiro T, Higuchi Y, Setoguuchi M, Yamamoto S, Nagai H, Nasu M, Vassalli P. Expression of osteopontin in a macrophage cell line and in transgenic mice with pulmonary fibrosis resulting from the lung expression of a tumor necrosis factor-α transgene. Ann NY Acad Sci. 1995;160:334-341.
15. Piguet PF, Vesin C. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur Respir J. 1994;7:515-518.
16. Peschon JJ, Torrance DS, Stocking KL, Glaccum MB, Otten C, Willis CR, Charrier K, Morrissey PJ, Ware CB, Moheler KM. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models for inflammation. J. Immunol. 1998;160:943-952.
17. Zheng L, Fisher G, Miller RE, Peschon J, Lynch D, Lenardo MJ. Induction of apoptosis in mature T cells by tumor necrosis factor. Nature. 1995;377:348-351.
18. Leon LR, Kozak W, Peschon J, Kluger MJ. Exacerbated febrile response to LPS, but not turpentine, in TNF double receptor-knockout mice. Am J Physiol. 1997;272:R563-R569.
19. Rothe J, Lessiauer W, Lotscher H, Lang Y, Koebel P, Kontgen F, Althage A, Zinkernagel R, Steinmetz M, Bluethmann H. Mice lacking the tumour necrosis factor receptor I are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature. 1993;364:798-802.
20. Pfeffer K, Matsuyama T, Kundig TM, Wakeham A, Kishihara K, Shahinian A, Wiegmann K, Ohashi PS, Kronke M, Mak TW. Mice deficient for the 55-kD tumor necrosis factor receptor are resistant to endotoxic shock, yet sucumb to L. monocytogenes infection. Cell. 1993;73:457-467.
21. Erickson SL, DeSauvage FJ, Kildy K, Carver-Moore K, Pitts-Meck S, Gillette N, Sheehan KCF, Schreiber RD, Goeddel DV, Moore MW. Decreased sensitivity to tumor necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature. 1994;372:560-563.
22. Kivirikko KI, Laitinen O, Prockop DJ. Modifications of a specific assay for hydroxyproline in urine. Anal Biochem. 1967;19:249-255.
23. Pulford KEF, Rigney EM, Micklem, KPl: a new monoclonal antibody that detects monocyte/ macrophage associated antigens in routinely processed tissue sections. J Clin Pathol. 1989;42:414-421.
24. Hulette CM, Downey BT, Burger PC. Macrophage markers in diagnostic neuropathology. Am J Surg Pathol. 1992;16:493-499.
25. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual. 2nd edition. New York: Cold Spring Harbor Laboratory; 1989.
26. 2 regulates macrophage-derived tumor necrosis factor gene expression. J Biol Chem. 1988;263:5380-5384.
27. Pelton RW, Johnson MD, Perkett KA, Gold LI, Moses HL. Expression of transforming growth faclor-β1, -β2, and -β3 mRNA and protein in the murine lung. Am J Respir Cell Mol Biol. 1991;5:522-530.
28. Stricter RM, Remick DG, Lynch JP, Spengler RN, Kunkel SL. Interleukin-2-induced tumor necrosis factor-alpha (TNF-α) gene expression in human alveolar macrophages and blood monocytes. Am Rev Respir Dis. 1989;139:335-342.
29. Bruce MC. Developmental changes in tropoelastin mRNA levels in rat lung: evaluation by in situ hybridization. Am J Respir Cell Mol Biol. 1991;5:344-350.
30. Smith RE, Stricter RM, Phan SH, Kunkel SL. C-C Chemokines: novel mediators of pro-fibrotic inflammatory response to bleomycin challenge. Am J Respir Cell Mol Biol. 1996;15:693-702.
31. Chandler DB, Hyde DM, Giri SN. Morphometric estimates of infiltrative cellular changes during the development of bleomycin-induced pulmonary fibrosis in hamsters. Am J Pathol. 1983;112:170-177.
32. Thrall RS, Barton RW, D'Amato DA, Sulavik SB. Differential cellular analysis of bronchoalveolar lavage fluid obtained at various stages during the development of bleomycin-induced pulmonary fibrosis. Am Rev Respir Dis. 1982;126:488-492.
33. Schrier DJ, Phan SH, McGarry BM. The effect of the nude (nu/nu) mutation on bleomycin-induced pulmonary fibrosis. Am Rev Respir Dis. 1983;127:614-617.
34. Kelley J. Cytokines of the lung. Am Rev Respir Dis. 1990;141:765-788.
35. Smith RE, Stricter RM, Zhang K, Phan SH, Standiford TJ, Lukacs NW, Kunkel SL. A role for C-C chemokines in fibrotic lung disease. J Leukoc Biol. 1995;57:782-787.
36. Denholm EM, Pham S. The effects of bleomycin on alveolar macrophage growth factor secretion. Am J Pathol. 1988;134-355-363.
37. Jordana M, Richards C, Irving LB, Gauldie J. Spontaneous in vitro release of alveolar-macrophage cytokines after intratracheal instillation of bleomycin in rats: characterization and kinetic studies. Am Rev Respir Dis. 1988;137:1135-1140.
38. Scheule RR, Perkins RC, Hamilton R, Holian A. Bleomycin stimulation of cytokine secretion by the human alveolar macrophage. Am J Physiol (Lung Cell Mol Physiol.) 1992;262:L386-L391.
39. Everson MP, Chandler DB. Changes in distribution, morphology, and tumor necrosis factor-α secretion of alveolar macrophage subpopulations during the development of bleomycin-induced pulmonary fibrosis. Am J Pathol. 1992;140:503-512.
40. Kolls JK, Ley D, Vasquez C, Odom G, Summer WR, Nelson S, Shellito J. Exacerbation of murine Pneumocystis carinii infection by adenoviral-mediated gene transfer of a TNF inhibitor. Am J Respir Cell Mol Biol. 1997;16:112-118.
41. Hoyt DG, Lazo JS. Alteration in pulmonary mRNA encoding procollagens, fibronectin and transforming growth factor-β precede bleomycin-induced pulmonary fibrosis in mice. J Pharmacol Exp Ther. 1988;246:765-771.
42. Khalil N, Bereznay O, Sporn M, Greenberg AH. Macrophage production of transforming growth factor b and fibroblast collagen synthesis in chronic pulmonary inflammation. J Exp Med. 1989;170:727-737.
43. Khalil N, Whitman C, Danielpour D, Greenberg AH. Regulation of alveolar macrophage transforming growth factor-β secretion by corticosteroids in bleomycin-induced pulmonary inflammation in the rat. J Clin Invest. 1993;92:1812-1818.
44. Giri SN, Hyde DM, Hollinger MA. Effect of antibody to transforming growth factor-β on bleomycin induced accumulation of lung collagen in mice. Thorax. 1993;48:959-966.
45. Piguet PF, Vesin C, Grau GE, Thompson RC. Interleukin 1 receptor antagonist (IL-lra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. Cytokine. 1993;5:57-61.